1. Taboada GF, Van Haute FR, Correa LL, Casini AF,
Gadelha MR. Etiologic aspects and management of acromegaly. Arq Bras Endocrinol Metabol 2005; 49:626-40.
2. Holdaway IM, Rajasoorya C. Epidemiology of
acromegaly. Pituitary 1999;2: 29-41.
3. Wright AD, Hill DM, Lowy C, Fraser TM. Mortality in
acromegaly. Q J Med 1970; 39: 1-16.
4. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An
audit of outcome of treatment in acromegaly. Q J
Med 1993;86: 293-9.
5. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome
Fig. 8. and survival in acromegaly. Clin Endocrinol (Oxf)
1994;41: 95-102.
45
Atatürk Üniv. Diş Hek. Fak. Derg.
Cilt:19, Sayı: 1, Yıl: 2009, Sayfa: 41-46
KARAALİOĞLU, YEŞİL DUYMUŞ
6. Swearingen B, Barker FG, Katznelson L, Biller BM,
Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;
83: 3419-26.
7. Ayuk J, Clayton RN, Holder G, Sheppard MC,
Steward PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89: 1613-7.
8. Melmed S. Acromegaly. N Engl J Med 1990; 322:
966-7.
9. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf)
1987;26: 481-512.
10. Ayuk J, Sheppard MC. Growth hormone and its
disorders. Postgrad Med J 2006;82;24-30.
11. Shaffer HL. A Textbook of Oral Pathology. Fourth
Edition. Philadelphia, W.B Saunders Company,
1983:654-6.
12. Melmed S. Medical progress: Akromegali. N Engl J
Med 2006;14:2558-73.
13. Damm N, Bouquot A. Oral & Maxillofacial
Pathology. 1th ed Philadelphia: W.B Saunders Company, 1995:606-7.
14. Cawson RA, Odel EW. Essential of Oral Pathology
and Oral Medicine. Sixth Edition. London: Churchill Livingstone, 1998:330-1.
15. Giustina A, Casanueva FF, Cavagnini F, Chanson P,
Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S. Diagnosis and treatment of acromegaly complication. J Endocrinol Invest
2003; 26: 1242-7.
16. Arosio M, Cannova S, Epaminonda P, Ronchi C,
Chiodini I, Adda G. Therapy for the syndromes of GH excess. J Endocrinal Invest 2003; 26(10
Suppl): 36-43.
17. Stuart C. White, Micheal J. Pharoah. Oral Radiology Principles and Interpretation. Fifth Edition, China, Mosby, St Louis, 2004:520-1.
18. Hurley DM, Ho KK. MSA Practice Essentials-Endocrinology 9: Pituiter disease in the adults. Med J Aust 2004; 180: 419-25.
19. Matta MP, Caron P. Acromegalic cardiomyopathy: are view of the literature. Pituitary, 2003; 6: 203¬6.
20. Berke JD, Moleres I. A removable appliance for the correction of maxillomandibular disproportion. J Prosthet Dent. 1967;17(2):172-7
21. Hampton RE. Acromegaly and resulting myofascial pain and temporomandibular joint dysfunction: review of the literature and report of case. J Am
Dent Assoc 1987; 114: 625-31.
22. Goodkind RJ. Prosthetic management of an acromegaly patient. J Am Dent Assoc.
1968;77:1327-30
Thank you for copying data from http://www.arastirmax.com
